Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

被引：0
|
作者：
Jeong Eun Kim
Baek-Yeol Ryoo
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词：
Sorafenib; Future Clinical Trial; Lower Efficacy; Antitumor Efficacy; Liver Function Deterioration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1641 / 1642
页数：1
相关论文
共 50 条
  • [1] Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Kim, Jeong Eun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Chang, Heung-Moon
    Suh, Dong Jin
    Lee, Han Chu
    Lim, Young-Suk
    Kim, Kang Mo
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1285 - 1290
  • [2] Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Jeong Eun Kim
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Heung-Moon Chang
    Dong Jin Suh
    Han Chu Lee
    Young-Suk Lim
    Kang Mo Kim
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1285 - 1290
  • [3] Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Fabio Farinati
    Anna Giacomin
    Veronica Vanin
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1639 - 1640
  • [4] Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
    Farinati, Fabio
    Giacomin, Anna
    Vanin, Veronica
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1639 - 1640
  • [5] Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function REPLY
    Kim, Jeong Eun
    Ryoo, Baek-Yeol
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1641 - 1642
  • [6] Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
    Pressiani, T.
    Boni, C.
    Rimassa, L.
    Labianca, R.
    Fagiuoli, S.
    Salvagni, S.
    Ferrari, D.
    Cortesi, E.
    Porta, C.
    Mucciarini, C.
    Latini, L.
    Carnaghi, C.
    Banzi, M.
    Fanello, S.
    De Giorgio, M.
    Lutman, F. R.
    Torzilli, G.
    Tommasini, M. A.
    Ceriani, R.
    Covini, G.
    Tronconi, M. C.
    Giordano, L.
    Locopo, N.
    Naimo, S.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2013, 24 (02) : 406 - 411
  • [7] Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
    Hollebecque, A.
    Cattan, S.
    Romano, O.
    Sergent, G.
    Mourad, A.
    Louvet, A.
    Dharancy, S.
    Boleslawski, E.
    Truant, S.
    Pruvot, F. -R.
    Hebbar, M.
    Ernst, O.
    Mathurin, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (10) : 1193 - 1201
  • [8] A Systematic Review of Sorafenib in Child-Pugh A Patients With Unresectable Hepatocellular Carcinoma
    Shen, Ai
    Tang, Chengyong
    Wang, Yefei
    Chen, Yong
    Yan, Xiong
    Zhang, Chao
    Liu, Rui
    Wei, Xufu
    Zhu, Yiyun
    Zhang, Hua
    Wu, Zhongjun
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2013, 47 (10) : 871 - 880
  • [9] Difficulties for providing evidence in hepatocellular carcinoma with Child-Pugh B liver function
    Edeline, Julien
    Blanc, Jean-Frederic
    LIVER INTERNATIONAL, 2023, 43 (02) : 274 - 275
  • [10] Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma
    de Guevara, Laura L.
    Dagher, Lucy
    Arruda, Vanessa M. V.
    Nakajima, Keiko
    Kudo, Masatoshi
    FUTURE ONCOLOGY, 2020, 16 (31) : 2511 - 2520
12345